These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28774425)

  • 21. Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).
    Galatsis P
    Expert Opin Ther Pat; 2017 Jun; 27(6):667-676. PubMed ID: 28117607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
    Deng X; Choi HG; Buhrlage SJ; Gray NS
    Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small-Molecule Inhibitors of LRRK2.
    Hatcher JM; Choi HG; Alessi DR; Gray NS
    Adv Neurobiol; 2017; 14():241-264. PubMed ID: 28353288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.
    Scott JD; DeMong DE; Greshock TJ; Basu K; Dai X; Harris J; Hruza A; Li SW; Lin SI; Liu H; Macala MK; Hu Z; Mei H; Zhang H; Walsh P; Poirier M; Shi ZC; Xiao L; Agnihotri G; Baptista MA; Columbus J; Fell MJ; Hyde LA; Kuvelkar R; Lin Y; Mirescu C; Morrow JA; Yin Z; Zhang X; Zhou X; Chang RK; Embrey MW; Sanders JM; Tiscia HE; Drolet RE; Kern JT; Sur SM; Renger JJ; Bilodeau MT; Kennedy ME; Parker EM; Stamford AW; Nargund R; McCauley JA; Miller MW
    J Med Chem; 2017 Apr; 60(7):2983-2992. PubMed ID: 28245354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1).
    Williamson DS; Smith GP; Acheson-Dossang P; Bedford ST; Chell V; Chen IJ; Daechsel JCA; Daniels Z; David L; Dokurno P; Hentzer M; Herzig MC; Hubbard RE; Moore JD; Murray JB; Newland S; Ray SC; Shaw T; Surgenor AE; Terry L; Thirstrup K; Wang Y; Christensen KV
    J Med Chem; 2017 Nov; 60(21):8945-8962. PubMed ID: 29023112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Type II LRRK2 inhibitors on signaling and mitophagy.
    Tasegian A; Singh F; Ganley IG; Reith AD; Alessi DR
    Biochem J; 2021 Oct; 478(19):3555-3573. PubMed ID: 34515301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel cinnoline-based inhibitors of LRRK2 kinase activity.
    Garofalo AW; Adler M; Aubele DL; Bowers S; Franzini M; Goldbach E; Lorentzen C; Neitz RJ; Probst GD; Quinn KP; Santiago P; Sham HL; Tam D; Truong AP; Ye XM; Ren Z
    Bioorg Med Chem Lett; 2013 Jan; 23(1):71-4. PubMed ID: 23219325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. QSAR Modelling to Identify LRRK2 Inhibitors for Parkinson's Disease.
    Sebastián-Pérez V; Martínez MJ; Gil C; Campillo NE; Martínez A; Ponzoni I
    J Integr Bioinform; 2019 Feb; 16(1):. PubMed ID: 30763264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening for chemical modulators for LRRK2.
    Mortiboys H
    Biochem Soc Trans; 2016 Dec; 44(6):1617-1623. PubMed ID: 27913670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2.
    Troxler T; Greenidge P; Zimmermann K; Desrayaud S; Drückes P; Schweizer T; Stauffer D; Rovelli G; Shimshek DR
    Bioorg Med Chem Lett; 2013 Jul; 23(14):4085-90. PubMed ID: 23768909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of potent and selective 5-azaindazole inhibitors of leucine-rich repeat kinase 2 (LRRK2) - Part 1.
    Osborne J; Birchall K; Tsagris DJ; Lewis SJ; Smiljanic-Hurley E; Taylor DL; Levy A; Alessi DR; McIver EG
    Bioorg Med Chem Lett; 2019 Feb; 29(4):668-673. PubMed ID: 30554956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective Inhibitors of G2019S-LRRK2 Kinase Activity.
    Garofalo AW; Bright J; De Lombaert S; Toda AMA; Zobel K; Andreotti D; Beato C; Bernardi S; Budassi F; Caberlotto L; Gao P; Griffante C; Liu X; Mengatto L; Migliore M; Sabbatini FM; Sava A; Serra E; Vincetti P; Zhang M; Carlisle HJ
    J Med Chem; 2020 Dec; 63(23):14821-14839. PubMed ID: 33197196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and Preliminary Evaluation of [
    Chen Z; Shao T; Gao W; Fu H; Collier TL; Rong J; Deng X; Yu Q; Zhang X; Davenport AT; Daunais JB; Wey HY; Shao Y; Josephson L; Qiu WW; Liang S
    ChemMedChem; 2019 Sep; 14(17):1580-1585. PubMed ID: 31365783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 Inhibitors.
    Keylor MH; Gulati A; Kattar SD; Johnson RE; Chau RW; Margrey KA; Ardolino MJ; Zarate C; Poremba KE; Simov V; Morriello GJ; Acton JJ; Pio B; Yan X; Palte RL; McMinn SE; Nogle L; Lesburg CA; Adpressa D; Lin S; Neelamkavil S; Liu P; Su J; Hegde LG; Woodhouse JD; Faltus R; Xiong T; Ciaccio PJ; Piesvaux J; Otte KM; Wood HB; Kennedy ME; Bennett DJ; DiMauro EF; Fell MJ; Fuller PH
    J Med Chem; 2022 Jan; 65(1):838-856. PubMed ID: 34967623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of potent azaindazole leucine-rich repeat kinase 2 (LRRK2) inhibitors possessing a key intramolecular hydrogen bond - Part 2.
    Shore DGM; Sweeney ZK; Beresford A; Chan BK; Chen H; Drummond J; Gill A; Kleinheinz T; Liu X; Medhurst AD; McIver EG; Moffat JG; Zhu H; Estrada AA
    Bioorg Med Chem Lett; 2019 Feb; 29(4):674-680. PubMed ID: 30522953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting LRRK2 in Parkinson's disease: an update on recent developments.
    Chan SL; Tan EK
    Expert Opin Ther Targets; 2017 Jun; 21(6):601-610. PubMed ID: 28443359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent Update on the Development of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors: A Promising Target for the Treatment of Parkinson's Disease.
    Patel A; Patel S; Mehta M; Patel Y; Langaliya D; Bhalodiya S; Bambharoliya T
    Med Chem; 2022; 18(7):757-771. PubMed ID: 35168510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells.
    Thirstrup K; Dächsel JC; Oppermann FS; Williamson DS; Smith GP; Fog K; Christensen KV
    Sci Rep; 2017 Aug; 7(1):10300. PubMed ID: 28860483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pyrazolopyridines as inhibitors of the kinase LRRK2: a patent evaluation (WO2011141756).
    Deng X; S Gray N
    Expert Opin Ther Pat; 2012 Jun; 22(6):709-13. PubMed ID: 22607035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.
    Estrada AA; Liu X; Baker-Glenn C; Beresford A; Burdick DJ; Chambers M; Chan BK; Chen H; Ding X; DiPasquale AG; Dominguez SL; Dotson J; Drummond J; Flagella M; Flynn S; Fuji R; Gill A; Gunzner-Toste J; Harris SF; Heffron TP; Kleinheinz T; Lee DW; Le Pichon CE; Lyssikatos JP; Medhurst AD; Moffat JG; Mukund S; Nash K; Scearce-Levie K; Sheng Z; Shore DG; Tran T; Trivedi N; Wang S; Zhang S; Zhang X; Zhao G; Zhu H; Sweeney ZK
    J Med Chem; 2012 Nov; 55(22):9416-33. PubMed ID: 22985112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.